Skip Therapeutics
Ness Ziona, HaMerkaz, Israel
About Skip Therapeutics
Skip Therapeutics develops precision, RNA-based, treatments for rare genetic diseases. Millions of people worldwide are affected by thousands of rare genetic disorders, yet the limited patient populations, further divided by patient-specific mutations, have hampered the discovery of effective treatments. Recent developments in RNA-therapeutics provide an enlarged molecular toolkit that can be used quickly and affordably to repair damaged genes' ability to make proteins. Computational techniques could be used to help identify sub-patient populations that would be eligible for treatment with RNA-based therapeutics and match molecular therapy options across the large landscape of known disease-causing mutations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Funding stage: Seed
- Last round: Seed (May 2021)
- Website: skiptx.com
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/skip-therapeutics-2567160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.